AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11780862 — intervention group
Group type: EXPERIMENTAL
Intervention: Repinotan (2.50 mg/day)
Number of subjects: 60
Study 11780862 — intervention group
Group type: EXPERIMENTAL
Intervention: Repinotan (various doses)
Number of subjects: 60
Study 11780862 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 9761783 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotenoid supplementation for 12 weeks
Number of subjects: 9
Study 9761783 — intervention group
Group type: EXPERIMENTAL
Intervention: Men from Ireland and the U.K.
Number of subjects: 9
Study 9761783 — intervention group
Group type: EXPERIMENTAL
Intervention: Women from all five countries
Number of subjects: 9
Study 9761783 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between mean levels of 8-oxo-dG and coronary heart disease mortality in men
Number of subjects: 9
Study 9761783 — intervention group
Group type: EXPERIMENTAL
Intervention: Colorectal cancer in men
Number of subjects: 9
Study 9761783 — intervention group
Group type: EXPERIMENTAL
Intervention: Stomach cancer in women
Number of subjects: 9
Study 7797214 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (50-100 mg per day)
Number of subjects: 31
Study 7797214 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 3044068 — intervention group
Group type: EXPERIMENTAL
Intervention: High sucrose diet (220 g of sucrose daily)
Number of subjects: 18
Study 3044068 — intervention group
Group type: COMPARATOR
Intervention: Complex carbohydrate (CHO) diet (less than 3 g of sucrose daily)
Number of subjects: 18
Study 3044068 — intervention group
Group type: EXPERIMENTAL
Intervention: High sucrose diet (220 g of sucrose daily) in patients with preexisting higher triglyceridemia
Number of subjects: 18
Study 31909680 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD) 300 mg
Number of subjects: 24
Study 31909680 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 30689551 — intervention group
Group type: EXPERIMENTAL
Intervention: Ai Chi
Number of subjects: 44
Study 30689551 — intervention group
Group type: EXPERIMENTAL
Intervention: Bad Ragaz Ring Method (BRRM)
Number of subjects: 44
Study 29149869 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding without nipple shield
Number of subjects: 38
Study 29149869 — intervention group
Group type: COMPARATOR
Intervention: Breastfeeding with nipple shield
Number of subjects: 38
Study 29149869 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer sucking duration
Number of subjects: 38
Study 29149869 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater proportion of feed sucked
Number of subjects: 38
Study 29149869 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater sucking efficiency
Number of subjects: 38
Study 26602302 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions related to sanitation, hygiene, and infant nutrition as part of the SHINE trial.
Number of subjects: 0
Study 26602302 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study 24341382 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD8309 (300 mg)
Number of subjects: 20
Study 24341382 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 21495995 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral lymecycline 300 mg with adapalene 0.1%-BPO 2.5% (A/BPO)
Number of subjects: 378
Study 21495995 — intervention group
Group type: COMPARATOR
Intervention: Oral lymecycline 300 mg with vehicle gel
Number of subjects: 378
Study 18430831 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous catheter drainage with negative pressure
Number of subjects: 85
Study 18430831 — intervention group
Group type: COMPARATOR
Intervention: Single-session alcohol sclerotherapy
Number of subjects: 85
Study 16484584 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine and high-dose cytosine (FLA)
Number of subjects: 405
Study 16484584 — intervention group
Group type: COMPARATOR
Intervention: Standard chemotherapy (ADE)
Number of subjects: 405
Study 16484584 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of G-CSF
Number of subjects: 405
Study 16484584 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of ATRA
Number of subjects: 405
Study 12916867 — intervention group
Group type: EXPERIMENTAL
Intervention: BEAC
Number of subjects: 71
Study 12916867 — intervention group
Group type: COMPARATOR
Intervention: BEAM
Number of subjects: 71
Study 10883411 — intervention group
Group type: EXPERIMENTAL
Intervention: Lecture supplemented by symbolic slides
Number of subjects: 40
Study 10883411 — intervention group
Group type: COMPARATOR
Intervention: Lecture without symbolic slides
Number of subjects: 40
Study 9347673 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac emulgel, applied at the painful site four times a day for 4 weeks
Number of subjects: 85
Study 9347673 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen hydroalcoholic gel, applied at the painful site four times a day for 4 weeks
Number of subjects: 85
Study 8212152 — intervention group
Group type: EXPERIMENTAL
Intervention: Short taper group (total PRED dose of 2275 mg/m2 over 86 days)
Number of subjects: 30
Study 8212152 — intervention group
Group type: EXPERIMENTAL
Intervention: Long taper group (total PRED dose of 6300 mg/m2 over 147 days)
Number of subjects: 30
Study 8212152 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 30
Study 3757605 — intervention group
Group type: EXPERIMENTAL
Intervention: Dispositional information (because he's real nice) for 9-year-olds
Number of subjects: 3
Study 3757605 — intervention group
Group type: EXPERIMENTAL
Intervention: Situational information (because he has a new game) for 9-year-olds
Number of subjects: 3
Study 3757605 — intervention group
Group type: EXPERIMENTAL
Intervention: Situational information (because he has a new game) for younger age groups (5 1/2 and 7 years old)
Number of subjects: 3
Study 3757605 — intervention group
Group type: COMPARATOR
Intervention: Dispositional information (because he's real nice) for younger age groups (5 1/2 and 7 years old)
Number of subjects: 3
Study 30121072 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative GDFT guided by PVI, administering fluid boluses of 3 ml/kg tetrastarch aiming at a PVI value below 10%.
Number of subjects: 150
Study 30121072 — intervention group
Group type: COMPARATOR
Intervention: Control group using esophageal Doppler for GDFT aiming for optimization of stroke volume.
Number of subjects: 150
Study 30121072 — intervention group
Group type: EXPERIMENTAL
Intervention: PVI group
Number of subjects: 150
Study 30121072 — intervention group
Group type: COMPARATOR
Intervention: Doppler group
Number of subjects: 150
Study 27359176 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-year multicomponent behavioral intervention
Number of subjects: 111
Study 27359176 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 111
Study 25722222 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal insulin therapy with glargine
Number of subjects: 42
Study 25722222 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal insulin therapy with detemir
Number of subjects: 42
Study 25722222 — intervention group
Group type: COMPARATOR
Intervention: Hypoglycemia episodes
Number of subjects: 42
Study 25722222 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in EPCs
Number of subjects: 42
Study 22840617 — intervention group
Group type: EXPERIMENTAL
Intervention: TAU + SCIT (n=21)
Number of subjects: 37
Study 22840617 — intervention group
Group type: COMPARATOR
Intervention: TAU (n=16)
Number of subjects: 37
Study 19828484 — intervention group
Group type: EXPERIMENTAL
Intervention: High magnesium levels (>1.0 mmol/l)
Number of subjects: 108
Study 19828484 — intervention group
Group type: COMPARATOR
Intervention: Normal magnesium levels (<=1.0 mmol/l)
Number of subjects: 108
Study 17984189 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine (Gln) supplementation (100 mg kg(‐1) body weight)
Number of subjects: 30
Study 17984189 — intervention group
Group type: COMPARATOR
Intervention: Alanine (Ala) supplementation (100 mg kg(‐1) body weight)
Number of subjects: 30
Study 17984189 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine (Gln) supplementation (once a day)
Number of subjects: 30
Study 17984189 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term Glutamine (Gln) supplementation
Number of subjects: 30
Study 17984189 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine (Gln) and Alanine (Ala) supplementation
Number of subjects: 30
Study 15793367 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivir (Cipla, Mumbai, India)
Number of subjects: 24
Study 15793367 — intervention group
Group type: COMPARATOR
Intervention: Epivir (GSK, Basingstoke, UK)
Number of subjects: 24
Study 14578253 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/day pioglitazone
Number of subjects: 39
Study 14578253 — intervention group
Group type: COMPARATOR
Intervention: Diet and exercise program
Number of subjects: 39
Study 10986000 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (20 treatments over 8 weeks)
Number of subjects: 34
Study 10986000 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture (20 treatments over 8 weeks)
Number of subjects: 34
Study 8635374 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin, vinblastine, and cisplatin
Number of subjects: 133
Study 8635374 — intervention group
Group type: COMPARATOR
Intervention: Mitomycin alone
Number of subjects: 133
Study 8635374 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin therapy
Number of subjects: 133
Study 8635374 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid therapy
Number of subjects: 133
Study 8635374 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin
Number of subjects: 133
Study 1514487 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-port infusion protocol
Number of subjects: 140
Study 1514487 — intervention group
Group type: COMPARATOR
Intervention: Double-port infusion protocol
Number of subjects: 140
Study 1514487 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-port and double-port protocols
Number of subjects: 140
Study 6487499 — intervention group
Group type: EXPERIMENTAL
Intervention: Enprofylline at plasma concentrations of 1.5 micrograms/ml
Number of subjects: 20
Study 6487499 — intervention group
Group type: EXPERIMENTAL
Intervention: Enprofylline at plasma concentrations of 2.9 micrograms/ml
Number of subjects: 20
Study 6487499 — intervention group
Group type: EXPERIMENTAL
Intervention: Enprofylline at plasma concentrations of 4.0 micrograms/ml
Number of subjects: 20
Study 6487499 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline at plasma concentrations of 5.5 micrograms/ml
Number of subjects: 20
Study 6487499 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline at plasma concentrations of 10.8 micrograms/ml
Number of subjects: 20
Study 6487499 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline at plasma concentrations of 15.2 micrograms/ml
Number of subjects: 20
Study 6487499 — intervention group
Group type: EXPERIMENTAL
Intervention: Enprofylline (above 2.9 micrograms/ml)
Number of subjects: 20
Study 6487499 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline infusion
Number of subjects: 20
Study 30765435 — intervention group
Group type: EXPERIMENTAL
Intervention: IONIS‐GCGRRx 200 mg
Number of subjects: 0
Study 30765435 — intervention group
Group type: EXPERIMENTAL
Intervention: IONIS‐GCGRRx 100 mg
Number of subjects: 0
Study 30765435 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30765435 — intervention group
Group type: EXPERIMENTAL
Intervention: IONIS‐GCGRRx 75 mg
Number of subjects: 0
Study 30765435 — intervention group
Group type: EXPERIMENTAL
Intervention: IONIS‐GCGRRx 50 mg
Number of subjects: 0
Study 29244746 — intervention group
Group type: EXPERIMENTAL
Intervention: Beetroot juice (70 mL, 5.6 mmol NO₃‐)
Number of subjects: 15
Study 29244746 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 26445182 — intervention group
Group type: EXPERIMENTAL
Intervention: Semiclosed hemorrhoidectomy
Number of subjects: 180
Study 26445182 — intervention group
Group type: EXPERIMENTAL
Intervention: Stapled hemorrhoidectomy
Number of subjects: 180
Study 26445182 — intervention group
Group type: COMPARATOR
Intervention: Open hemorrhoidectomy
Number of subjects: 180
Study 24402698 — intervention group
Group type: EXPERIMENTAL
Intervention: High working memory capacity group
Number of subjects: 2
Study 24402698 — intervention group
Group type: EXPERIMENTAL
Intervention: Low working memory capacity group
Number of subjects: 2
Study 24402698 — intervention group
Group type: COMPARATOR
Intervention: Overall WMC groups
Number of subjects: 2
Study 23051880 — intervention group
Group type: EXPERIMENTAL
Intervention: Video distraction (video clip of child's preference during induction)
Number of subjects: 89
Study 23051880 — intervention group
Group type: COMPARATOR
Intervention: Traditional distraction methods (control group)
Number of subjects: 89
Study 19364250 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous apomorphine co-administered with trimethobenzamide or domperidone premedication
Number of subjects: 0
Study 19364250 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous infusion of apomorphine
Number of subjects: 0
Study 17707934 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-randomized trials
Number of subjects: 0
Study 15024927 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised treatment with primaquine (0.25 mg PQ/kg body weight) once per day for 14 days
Number of subjects: 595
Study 15024927 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsupervised treatment with primaquine (14 doses provided upon enrollment)
Number of subjects: 595
Study 15024927 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 595
Study 15960211 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac intramuscular single dose
Number of subjects: 64
Study 15960211 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 15960211 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups received morphine by Patient Controlled Analgesia (PCA)
Number of subjects: 64
Study 10494364 — intervention group
Group type: EXPERIMENTAL
Intervention: Active warming (WarmTouch 5000, 41-42 degrees C)
Number of subjects: 54
Study 10494364 — intervention group
Group type: COMPARATOR
Intervention: No active warming
Number of subjects: 54
Study 8739682 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% timolol solution given twice daily
Number of subjects: 223
Study 8739682 — intervention group
Group type: COMPARATOR
Intervention: 0.5% timolol in gel‐forming solution given once daily
Number of subjects: 223
Study 8739682 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% timolol in gel‐forming solution
Number of subjects: 223
Study 8739682 — intervention group
Group type: COMPARATOR
Intervention: 0.5% timolol solution
Number of subjects: 223
Study 1890650 — intervention group
Group type: EXPERIMENTAL
Intervention: B2 agonists kallidin
Number of subjects: 14
Study 1890650 — intervention group
Group type: EXPERIMENTAL
Intervention: B2 agonists bradykinin
Number of subjects: 14
Study 1890650 — intervention group
Group type: EXPERIMENTAL
Intervention: [Des-Arg9]-bradykinin (B1 agonist)
Number of subjects: 14
Study 1890650 — intervention group
Group type: COMPARATOR
Intervention: Vehicle placebo
Number of subjects: 14
Study 6125727 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium supplementation (60 mmol/day)
Number of subjects: 23
Study 6125727 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 30550313 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-regulation with large changes (LC)
Number of subjects: 599
Study 30550313 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-regulation with small changes (SC)
Number of subjects: 599
Study 30550313 — intervention group
Group type: COMPARATOR
Intervention: Self-regulation interventions (both SC and LC)
Number of subjects: 599
Study 30550313 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater self-weighing frequency
Number of subjects: 599
Study 30009127 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS over the left inferior frontal gyrus (IFG)
Number of subjects: 24
Study 30009127 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 24
Study 27247173 — intervention group
Group type: EXPERIMENTAL
Intervention: Employment
Number of subjects: 2055
Study 27247173 — intervention group
Group type: COMPARATOR
Intervention: Unemployed
Number of subjects: 2055
Study 24979307 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelnidipine
Number of subjects: 14
Study 24979307 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 14
Study 22162258 — intervention group
Group type: EXPERIMENTAL
Intervention: Nigella sativa oil capsules 500 mg twice/day
Number of subjects: 40
Study 22162258 — intervention group
Group type: COMPARATOR
Intervention: Placebo (starch filled capsules)
Number of subjects: 40
Study 21149761 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin (0.4 mg/d)
Number of subjects: 129
Study 21149761 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study 17605681 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral radiofrequency collagen denaturation
Number of subjects: 21
Study 17605681 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 21
Study 15657155 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-sample at-home FOBT
Number of subjects: 3121
Study 15657155 — intervention group
Group type: COMPARATOR
Intervention: Digital FOBT
Number of subjects: 3121
Study 12127708 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaclor (40 mg/kg/day in two doses for 5 days)
Number of subjects: 384
Study 12127708 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin (40 mg/kg/day in three doses for 10 days)
Number of subjects: 384
Study 10450594 — intervention group
Group type: EXPERIMENTAL
Intervention: External nasal dilator
Number of subjects: 18
Study 10450594 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 10450594 — intervention group
Group type: COMPARATOR
Intervention: Lateral position
Number of subjects: 18
Study 10450594 — intervention group
Group type: COMPARATOR
Intervention: NREM sleep
Number of subjects: 18
Study 10450594 — intervention group
Group type: COMPARATOR
Intervention: Stage 2 sleep
Number of subjects: 18
Study 8539152 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast chronotropic response (lower rate abruptly programmed to the expected value at 50% metabolic reserve)
Number of subjects: 10
Study 8539152 — intervention group
Group type: COMPARATOR
Intervention: DDD (lower rate 60 beats/min)
Number of subjects: 10
Study 8539152 — intervention group
Group type: COMPARATOR
Intervention: Overpaced (lower rate at least 80% of the age predicted maximum)
Number of subjects: 10
Study 8539152 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast chronotropic response
Number of subjects: 10
Study 30817452 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP treatment
Number of subjects: 131
Study 27626675 — intervention group
Group type: EXPERIMENTAL
Intervention: Stooped posture during negative mood induction
Number of subjects: 351
Study 27626675 — intervention group
Group type: EXPERIMENTAL
Intervention: Stooped posture
Number of subjects: 351
Study 27626675 — intervention group
Group type: COMPARATOR
Intervention: Cognitive reappraisal instructions
Number of subjects: 351
Study 25920384 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing, 6 weeks' worth of nicotine patches and gum, faxed referral to the state smokers' quitline, booster call, and brochure.
Number of subjects: 778
Study 25920384 — intervention group
Group type: COMPARATOR
Intervention: Brochure providing quitline information.
Number of subjects: 778
Study 23616495 — intervention group
Group type: EXPERIMENTAL
Intervention: Colistin plus rifampicin 600 mg every 12 hours intravenously
Number of subjects: 210
Study 23616495 — intervention group
Group type: COMPARATOR
Intervention: Colistin alone, 2 MU every 8 hours intravenously
Number of subjects: 210
Study 21863679 — intervention group
Group type: EXPERIMENTAL
Intervention: Effective-site target controlled infusion (TCI) of propofol with initial target concentration of 1.5 microg/ml.
Number of subjects: 60
Study 21863679 — intervention group
Group type: COMPARATOR
Intervention: Manually controlled infusion (MCI) of propofol with initial bolus 0.5 mg/kg and initial infusion rate 1.5 mg/kg/hr.
Number of subjects: 60
Study 21863679 — intervention group
Group type: EXPERIMENTAL
Intervention: Effective-site target controlled infusion (TCI) of propofol.
Number of subjects: 60
Study 21863679 — intervention group
Group type: COMPARATOR
Intervention: Manually controlled infusion (MCI) of propofol.
Number of subjects: 60
Study 18060280 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium picosulfate
Number of subjects: 80
Study 18060280 — intervention group
Group type: COMPARATOR
Intervention: Mannitol
Number of subjects: 80
Study 17564405 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular advancement splint
Number of subjects: 73
Study 17564405 — intervention group
Group type: COMPARATOR
Intervention: Inactive oral device
Number of subjects: 73
Study 11827087 — intervention group
Group type: EXPERIMENTAL
Intervention: MP (modus ponens) premise forms
Number of subjects: 0
Study 11827087 — intervention group
Group type: EXPERIMENTAL
Intervention: AC (affirming-the-consequent) premise forms
Number of subjects: 0
Study 11827087 — intervention group
Group type: EXPERIMENTAL
Intervention: MP and AC arguments
Number of subjects: 0
Study 11827087 — intervention group
Group type: EXPERIMENTAL
Intervention: AC inferences
Number of subjects: 0
Study 10613279 — intervention group
Group type: EXPERIMENTAL
Intervention: Day-stay only
Number of subjects: 131
Study 10613279 — intervention group
Group type: COMPARATOR
Intervention: Overnight-stay
Number of subjects: 131
Study 7555937 — intervention group
Group type: EXPERIMENTAL
Intervention: Pull method with antibiotic prophylaxis (amoxycillin‐clavulanic acid 3 x 1.2 g i.v. over 24 hours); 37 patients
Number of subjects: 100
Study 7555937 — intervention group
Group type: COMPARATOR
Intervention: Pull method without antibiotic prophylaxis; 34 patients
Number of subjects: 100
Study 7555937 — intervention group
Group type: COMPARATOR
Intervention: Push method without antibiotic prophylaxis; 29 patients
Number of subjects: 100
Study 7555937 — intervention group
Group type: EXPERIMENTAL
Intervention: Pull method with antibiotic prophylaxis; 37 patients
Number of subjects: 100
Study 1683094 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium carbonate added to neuroleptics
Number of subjects: 0